|
- OPDIVO® (nivolumab)
OPDIVO® (nivolumab) is a prescription medication that treats certain types of cancer Read the indications, side effects, and more Please see Indication and Important Safety Information
- Subcutaneous Injection | OPDIVO® (nivolumab) + Qvantig™ (hyaluronidase . . .
Learn more about OPDIVO® (nivolumab) + Qvantig™ (hyaluronidase-nvhy) as a subcutaneous injection treatment option for your fight against cancer Please see Indication and Important Safety Information
- Clinical trial results for - OPDIVO
See how OPDIVO® (nivolumab) + YERVOY® (ipilimumab) performed in a clinical trial as first-line treatment for adults with advanced non-small cell lung cancer that tested positive for PD-L1 Please see Indication and Important Safety Information
- Financial Information: Cost, Access Affordability - OPDIVO
Important Facts About OPDIVO Qvantig ™ (nivolumab + hyaluronidase-nvhy) This is a summary of important information that you need to know about OPDIVO Qvantig Your healthcare team can work with you to help answer any questions you may have about this medication
- Frequently Asked Questions (FAQ) | OPDIVO® (nivolumab)
Find answers to frequently asked questions about OPDIVO® (nivolumab) including what OPDIVO® is, how immunotherapy works, and what are the side effects of OPDIVO® Please see Indication and Important Safety Information
- OPDIVO ® with You
Sign up for OPDIVO with You, a support program that offers helpful information if you are about to start or are currently on OPDIVO® (nivolumab) or an OPDIVO®-based combination Please see Indication and Important Safety Information
- OPDIVO® Support Patient Resources | OPDIVO® (nivolumab)
Whether you're a new or continuing OPDIVO® (nivolumab) patient, find resources that can support you through a cancer diagnosis and during treatment Access helpful resources and find assistance for OPDIVO® patients here
- Advanced Kidney Cancer | Clinical Trial Results | OPDIVO® (nivolumab . . .
See how OPDIVO® (nivolumab) + CABOMETYX® (cabozantinib) performed in a clinical trials for adults with previously untreated kidney cancer that has spread (advanced renal cell carcinoma or aRCC) Please see Indication and Important Safety Information
|
|
|